Time: 2024-05-27
Hemangiosarcoma, an aggressive cancer in dogs that originates from blood vessel cells, often leads to rapid spread throughout the body. This type of cancer commonly affects organs like the spleen, liver, heart, and muscles, causing significant bleeding and other symptoms in affected dogs. Dr. Heather Gardner, an expert in veterinary oncology, highlights the challenges of diagnosing and treating hemangiosarcoma due to its elusive nature and tendency to metastasize early.
Despite being prevalent in various breeds, golden retrievers are notably predisposed to hemangiosarcoma. Dr. Gardner emphasizes the importance of early detection, as the cancer typically disseminates to different body parts by the time of diagnosis. She is pioneering a new liquid biopsy technique to identify specific cancer markers in blood samples, aiding in the detection and monitoring of hemangiosarcoma.
Moreover, this innovative research not only benefits dogs but also holds promise for improving liquid biopsy tests in humans with similar cancers like angiosarcoma. The study aims to optimize early cancer detection and tailor treatment strategies based on genetic mutations identified through liquid biopsy testing.
Collaborating with experts like Dr. Cheryl London, Dr. Gardner is part of a comprehensive project that integrates clinical trials in pet dogs to enhance cancer detection and treatment outcomes. By analyzing genetic mutations in hemangiosarcoma and correlating them with personalized therapies, the team hopes to revolutionize the management of this aggressive cancer.
Through the utilization of cutting-edge technology and interdisciplinary collaboration, Dr. Gardner and her team are paving the way for more effective cancer management strategies, benefiting both veterinary and human medicine.
Business
